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Abstract 
DNA is the repository of genetic information of an organism and contains the information that regulates 
its proper morphogenesis. Every day, our DNA is attacked by various DNA damaging agents. Our cells 
developed several safeguarding mechanisms, which protect DNA from different kinds of damages. 
Sometimes, these defence mechanisms fail and are unable to repair the DNA damage. This failure can 
negatively influence various biological mechanisms, e.g. cell cycle arrest and/or cell death, and the 
DNA damaged cells may thus turn into a cancer cells. Cancer cells can later become metastatic and 
spread to other parts of the body. If their spread is not controlled, they can cause serious illness and even 
death of an individual. Various cancer treatments aim to inhibit tumor progression by inducing cell 
cycle arrest and/or cell death, which are significantly mediated by the p53 family of proteins. 
p73 is the second member to be identified within the p53 family and shares structure and functions with 
p53. P73 generates various isoforms, which include full-length transcriptionally active (TA) isoforms 
and amino-terminal transactivation domain-deficient (ΔN) isoforms. TA isoforms of p73 are considered 
to act as tumor suppressors, whereas the ∆N isoforms of p73 act functionally analogous to other 
oncoproteins by counteracting the tumor suppressive functions of p53 and TAp73. In contrast to 
the P53, which is frequently mutated in a variety of human cancers, P73 mutations are very rarely 
found. However, altered expression of p73 or expression of abnormal p73 splicing variants is frequently 
detected in different type of cancers. In some cancer cell lines overexpression of TAp73α confers 
resistance to anticancer chemotherapeutic agents. 
In our interest to identify transcriptional activities and molecular mechanisms of p73 isoforms that 
influence drug-induced apoptosis, we found that TAp73α inhibits drug-induced apoptosis by inducing 
the expression of Hsp72, a cell survival protein, in small cell lung carcinoma cells. TAp73α can also 
prevent caspase-2-induced apoptosis via inhibiting its enzymatic activity. In contrast, TAp73β induces 
the expression of p57Kip2, which holds tumor suppressor properties. The pro-apoptotic effects of the 
TAp73β isoform seem to partially depend on the induction of p57Kip2. We discovered that different p73 
isoforms transactivate cell cycle and apoptosis regulating gene promoters with different capability in a 
cell type-specific manner. Furthermore, we identified a functional cooperation between p53 family 
members, in which transcriptional activity of a DBD mutated isoform of TAp73α depends on the p53 
status of the cell to transactivate cell cycle regulating P21 gene promoter. 
In conclusion, our findings help to understand the isoform-specific transcriptional activities of p73 that 
determines its pro- and anti-apoptotic effects, upon drug treatment. These findings are expected to help 
in the development of new strategies to target cancer efficiently based on the p73 isoform present in the 
tumour and based on the context of the cell. 
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1. Abbreviations  
AIF  Apoptosis inducing factor  
Apaf-1 Apoptotic peptidase activating factor-1 
asDNA Anti-sense DNA 
ATP  Adenosine 5’ triphosphate 
Bax  Bcl2-associated X protein 
Bcl-2  B-cell lymphoma/leukemia-2 
Bcl-XL B-cell lymphoma-extra large 
BH domain Bcl-2 homology domain 
Bid  BH3 interacting domain death agonist  
CAD  Caspase-activated DNase  
CBP  cAMP response element-binding protein (CREB)-binding protein  
CD95  Cluster of differentiation 95  
CDK  Cyclin-dependent kinase 
c-FLIP Cellular FADD like IL-1beta-converting enzyme inhibitory protein 
ChIP  Chromatin immunoprecipitation 
CKI  CDK inhibitor 
Cyt c  Cytochrome C 
DBD  DNA binding domain  
DD  Death domain 
DED  Death effector domain 
DISC  Death inducing signaling complex  
DNA  Deoxyribonucleic acid 
Egr-1  Early growth response-1 
Endo G  Endonuclease G 
ER  Endoplasmic reticulum  
FADD Fas-associated death domain 
FLICE Fas-associated death domain-like interleukin-1beta-converting enzyme 
FLIP  FLICE inhibitory protein  
HCC  Hepato cellular carcinoma  
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Hsp  Heat shock protein 
IAP  Inhibitors of apoptosis protein  
ICAD Inhibitor of caspase-activated DNase  
JNK  c-Jun N-terminal kinase  
LMMP loss of mitochondrial transmembrane potential  
LMP  lysosomal membrane permeabilization 
LOH  Loss of heterozygosity 
MDM2 Mouse double minute 2 
MOMP Mitochondrial outer membrane permeabilization  
mRNA  messenger RNA 
NGF  Nerve growth factor  
NSCLC Non-small cell lung carcinoma  
NuMa Nuclear mitotic apparatus protein 
OD  Oligomerization domain  
p53RE p53 response element 
PARP Poly (ADP-ribose) polymerase 
PIAS-1 Protein inhibitor of activated signal transducer and activator of  
  transcription-1(STAT-1) 
Pin1  Protein interacting with never in mitosis A1  
pRB  Retinoblastoma protein  
PUMA p53-upregulated modulator of apoptosis  
RNA   Ribonucleic acid  
SAM  Sterile alpha motif  
SCLC Small cell lung carcinoma 
siRNA Small interfering ribonucleic acid 
Smac/Diablo Second mitochondria-derived activator of caspase/Direct inhibitor of 
  apoptosis-binding protein with low pl  
SUMO-1 Small ubiquitin-like modifier-1 
TA domain Transactivation domain  
tBid  Truncated BH3 interacting domain death agonist 
TF  Transcription factor 
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TM domain Transmembrane domain 
Tyr  Tyrosine  
UV  Ultraviolet 
WT  Wild-type 
Yap  Yes associated protein  
ZEB1 Zinc finger E-box Binding homeobox 1 
ΔN isofrom Amino-terminally truncated isoform 
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2. Introduction 
DNA is the repository of genetic information in every living cell and its integrity and stability are 
essential during all stages of life. DNA replication and gene expression are regulated differently 
during various stages of life of an organism. For example, in early Drosophila and Xenopus 
embryogenesis, the duration of S phase lasts for minutes [27, 133], but in fully differentiated cell 
types S phase can last longer than ten hours [232]. The developmental signals and molecular 
mechanisms that control the transcription and replication of DNA during development are poorly 
understood and they are partly regulated by various families of proteins, like minichromosome 
maintenance (MCM) family [103], transforming growth factor (TGF)-beta family [340], B-cell 
lymphoma/leukemia-2 (Bcl-2) family [120], and the p53 family [64]. The p53 family proteins are 
transcription factors, regulate development, cell cycle, apoptosis and DNA damage response with 
different capabilities [177]. 
 
 
 
3. The P53 gene family  
In 1979, six groups of investigators independently reported the discovery of a ~53 kDa protein in 
human and mouse cells. Five of them reported binding of a ~53 kDa protein to the large T-
antigen of simian virus 40 (SV40) in cells infected with this virus and the sixth group found that this 
protein is expressed in several types of mouse tumor cells [72, 176]. The discovered protein was 
named p53 and the gene encoding p53 (i.e., P53) was initially believed to be an oncogene [87, 138]. 
However, subsequent studies revealed its potential role as a tumor suppressor protein [13, 176, 
228]. Two proteins named p73 and p63 were identified in 1997 and 1998 respectively and these 
proteins share structural and functional similarities with p53. Later onwards, P53, P63 and P73 
genes are collectively regarded as “ The P53 gene family’’, which encodes for the transcription 
factors (TFs) p53, p63 and p73, respectively.  
Members of the p53 family contain an amino-terminal transactivation domain (TAD), a central 
DNA binding domain (DBD) and a carboxy-terminal oligomerization domain (OD). However, p63 
and p73 also contain an additional sterile alpha motif (SAM) domain, which is expected to be 
involved in protein-protein interactions. p73 contains an additional TA domain and a transcriptional 
inhibitory domain (TID) within its carboxy-terminal region [268]. The three members of the P53 
family display highest sequence similarity within the TAD, DBD and OD (Fig.1) [331]. At the 5´-
terminal region, all members of P53 gene family contain two alternative promoters (p1 and p2), 
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which produce full-length transactivating (TA) and 5´-terminally truncated (ΔN) primary mRNA 
transcripts respectively. The primary transcripts generated from these two promoters undergo 
alternative splicing at both 5´- and 3´-terminal regions to generate various 5´ and 3´ mRNA 
isoforms [196, 207, 331]. 
 
 
 
 
Figure 1. Structure of the human p53 family. Functional domains of p53 family members are depicted. 
Members of the p53 family contain transactivation domain (TAD), DNA-binding domain (DBD), 
oligomerization domain (OD) and they are indicated in subtle red, purple and orange colours respectively. 
However, P63 and P73 genes encode an additional sterile α motif (SAM) domain, which is indicated in 
subtle Aqua colour. Percentage similarity and identity (in brackets) of residues between p53, p63, and p73 is 
indicated. Values are represented for each individual structural domain [196, 207, 279, 331]. 
 
 
p53 response elements (p53REs) are 20 base pair (bp) DNA segments recognized by the TF p53. 
p53REs are located within the promoter/enhancer regions across the genome and they are 
associated with genes that regulate various biological processes, for example, development, 
differentiation, cell cycle and apoptosis [6, 48, 148, 243]. p53, p63 and p73 proteins are functionally 
active as tetramers and they recognise p53REs through their DBDs [176, 278]. Though they share 
structural similarities, their roles in the above mentioned biological processes are dissimilar [176, 
254, 331]. 
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3.1. P53 gene 
The P53 gene encodes the TF p53, which is regarded as ‘‘the guardian of the genome’’ [85]. 
Identification of p53 created a new era in the cancer research. This protein has attracted the interest 
of many researchers as it is frequently mutated or deleted in a variety of cancers [329] and p53 
knockout mice display spontaneous tumors [83].  
P53 contain two distinct upstream promoters (p1´ and p1) and an internal promoter (p2) located in 
intron four. The use of alternative promoters can lead to the expression of three different 5´-terminal 
primary mRNA transcripts that give rise to TA, Δ40p53 and Δ133p53 isoforms. Primary transcripts 
generated from p1 or p1′ promoters undergo alternative splicing at the 5´-terminal region in intron-2 
and generate Δ40p53 protein isoforms. Alternative initiation of translation at ATG-40 also 
generates Δ40p53 protein isoforms. The p2 promoter encodes Δ133p53 protein isoforms. Δ133p53 
isoforms are amino-terminal truncated proteins and do not contain the entire transactivation domain 
and a part of the DNA binding domain [25, 61, 155, 196, 211, 265]. The primary transcripts 
generated from p1´, p1 and p2 promoters can undergo alternative splicing within the 3´-terminal 
region and generate α, β, γ, δ, ε, ζ and ΔE6 isoforms [196, 332]. 
 
 
Figure 2. Structure of the human P53 gene. Alternative promoters (p1, p1′ and p2) and alternative splicing 
variants of P53 are depicted. p1 or p1′ promoters of the P53 gene encodes amino-terminal transactivation 
(TA) domain containing p53 isoforms. Δ40p53 protein isoforms are encoded from p1 or p1′ promoters and 
they are amino-terminal truncated proteins due to alternative splicing of intron-2 and/or alternative initiation 
of translation at ATG-40. Δ40p53 protein isoforms contain only a part of the transactivation domain. Amino-
terminal truncated Δ133p53 isoforms, which lack the TA domain and a part of the DBD, are encoded from 
the p2 promoter of the P53 gene. Each 5´-terminal mRNA isoform can undergo alternative splicing at the 3´-
terminal region and generates α, β, γ, δ, ε, ζ and ΔE6 carboxy-terminal p53 isoforms. Numbers in the 
rectangles indicate the exons encoding the p53 protein [194, 196, 219, 332]. 
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p53 is active as a tetramer [54] and it transactivates genes involved in various biological processes 
like cell cycle and apoptosis [15]. The P53 gene is commonly mutated in a variety of human 
cancers [85, 127] and mutations in this gene are reported in more than 50% of the human cancers 
[329]. Most of the P53 mutations are located in its DBD region. Some mutations in DBD of p53 do 
not completely abolish its transcriptional activities, but in many cases these mutations alter 
transcriptional activities of p53. Donehower et al., in 1992 first reported that P53
-/-
 mice are viable, 
but highly susceptible to spontaneous tumorigenesis [83]. p53 knockout mice revealed that p53 
plays an important role in tumor suppression [83, 343]. p53 regulates cell cycle related genes, and 
thereby controls G1 and G2/M cycle checkpoints [2, 37, 125, 203, 264]. p53 induces expression of 
pro-apoptotic proteins and induces apoptosis [34, 239, 252, 255, 281, 328]. 
Both the amino- and carboxy-terminal domains of the p53 protein undergo post-translational 
modifications like phosphorylation and acetylation, which regulate the functions of p53 [63, 205]. 
Mutant p53 alters the transcriptional activities of the wild-type (WT) p53 [357] and in some cases it 
contributes to chemoresistance [85]. A subset of tumor derived mutant forms of p53 interacts with 
p73 and alters its transcriptional activities [106].  
p53 is also associated with the regulation of normal embryonic development. P53
-/-
 mice exhibit 
abnormalities in the central nervous system [7]. p53-deficient mice embryos display abnormal brain 
and head morphology, and exhibit exencephaly [270]. Decreased pregnancy rate and litter size were 
observed in matings with P53
-/-
 female mice, but not with P53
-/-
 male mice [130]. 
 
3.2. P63 gene 
The P63 gene was identified in 1998 and is located at chromosome 3q27–29 [345]. P63 encodes the 
TF p63, which is renowned as ‘‘the guardian of the female germ line’’ [21]. Due to use of 
alternative promoters (p1 and p2) it can produce both TA and ΔN 5´-terminal mRNA isoforms. 
Moreover, alternative splicing within the 3´-terminal region of these two primary transcripts 
generates various carboxy-terminal p63 isoforms named α, β, γ, δ and ε [332]. ΔNp63 isoforms 
counteract the transcriptional activities of TAp63 isoforms and p53 [221]. Similar to other TFs of 
the p53 family, p63 is active as a tetramer. The p63 isoforms can form complexes among 
themselves or with mutant p53 and p73. These multiple interactions increase the complexity in 
understanding the biological roles of the p63 [174, 185]. 
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Figure 3. Structure of the human P63 gene. The P63 gene contains two alternative promoters (p1 and p2). 
Full-length transactivation domain containing TAp63 isoforms are encoded from the p1 promoter of the P63 
gene. ΔNp63 isoforms, which lack the transactivation domain, are encoded from the p2 promoter of the P63 
gene. Numbers in the rectangles indicate the exons encoding the p63 protein [35, 36, 219]. 
 
 
p63 plays key roles during embryonic development and regulates ectodermal structures such as hair, 
skin, teeth and nails [210, 260]. It also regulates the development of limbs, facial features and the 
urinary system. Mutations in the P63 gene are associated with various disorders like Rapp-Hodgkin 
syndrome (RHS), ectrodactyly-ectodermal dysplasia clefting (EEC) syndrome, limb mammary 
syndrome (LMS) ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome and split 
hand/foot malformation type 4 (SHFM4) [260]. P63
-/-
 mice revealed that p63 plays an important 
role in regulating the normal development of epithelia, wound healing, and in preventing the 
premature ageing as well as tumorigenesis [19, 100, 298]. 
  
p63 regulates various cellular activities like cell growth, proliferation, differentiation, cell adhesion, 
cell cycle and apoptosis [30, 45, 98, 341]. Altered expression levels of the p63 protein are detected 
in various cancers such as bladder, prostate, lung, breast and cervical cancer [334]. 
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3.3. P73 gene 
P73 was identified in 1997 and maps to the chromosome region 1p36.33, a locus identified to be 
deleted or hypermethylated in various human cancers [29, 44, 140, 149, 154, 292]. Since its 
discovery it has been extensively studied, mainly due to its remarkable similarity with P53. The 
P73 gene encodes the TF p73. Depending on the cell type, p73 is expressed as several structural 
variants, which may differ either at the amino- and/or carboxy-terminal region. Two different 5´-
terminal primary mRNA transcripts (TA and ΔN) are generated as a result of transcription of the 
alternative promoters (p1 and p2) of the P73 gene. These primary mRNA transcripts undergo 
alternative splicing at the 5´-terminal region and generate ΔEx2, ΔEx2/3 and ΔN´ isoforms [290, 
291]. 
Subsequently, 5´-terminal primary mRNA transcripts undergo alternative splicing at the 3´-terminal 
region and generate nine different putative isoforms named, α, β, γ, δ, ε, θ, ζ, η and η1 [332]. 
Among all p73 isoforms, TAp73α is the longest and contains a proline rich SAM domain. TAp73β 
is shorter than TAp73α and lacks the carboxy-terminal SAM domain found in p73α. Differential 
expression of TA and ΔN isoforms of p73 is expected to be influenced by the regulatory elements 
present in each promoter and by tissue-specific splicing of its primary mRNA transcripts. 
All p73 isoforms contain a DBD and an OD. The carboxy-terminal α and ζ isoforms contain the 
entire SAM domain. The OD is responsible for homooligomerization and for formation of 
heterodimers with p63 [65]. ΔNp73 isoforms lack the transactivation domain and are frequently 
overexpressed in various human cancers, but not in the corresponding normal tissues [11, 353].  
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(A)  
 
(B)  
 
Figure 4. The structure of the human P73 gene. (A) P73 gene contains two alternative promoters (p1 and 
p2). Alternative splicing of the primary transcripts, which are generated from these two promoters undergo 
alternative splicing both at 5´- and 3´-terminal regions and generates several mRNA variants. (B) Amino-
terminal (left) and carboxy-terminal (right) isoforms of p73 are depicted. Theoretically 45 different isoforms 
can be generated from the P73 gene as a result of alternative splicing [48, 194, 206, 248, 268, 288]. Initial 
positions of the amino acids that located at different domains are indicated.  
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3.4. Interplay between p53 family isoforms 
Protein-protein interactions regulate protein stability, activity, and its biological function. These 
interactions may cause reversible conformational changes in proteins that influence their functions 
in various signaling networks. These interactions are reversible and influenced by various factors. 
Due to use of alternative promoters and alternative splicing, members of the P53 gene family 
generate a vast number of protein isoforms. These individual protein isoforms have different 
capabilities to regulate various biological processes like development, differentiation, apoptosis and 
DNA damage response [177]. Moreover, the interactions between these family members have 
significant impact on each other’s function. 
In head and neck squamous cell carcinomas and in breast tumors ΔNp63α inhibits pro-apoptotic 
effects of TAp73 [174]. In non-small cell lung carcinoma (NSCLC) H1299 cells, transcriptional 
activities of p73α, β, γ and δ isoforms over the P21gene promoter are inhibited by a mutant p53 
[295, 337]. A transcriptionally inactive mutant of p73α containing an amino acid substitution 
(R292H) within its DBD, stabilizes and activates p53 to induce P21 expression [213]. This suggests 
that mutations in p73 might not cause a loss of its tumor suppressive activities as they still have the 
ability to stabilize and activate p53 [213]. 
ΔNp73 can form complexes with WT p53 in an ovarian carcinoma and endometrial carcinoma. 
Surprisingly, these complex formations are identified only in the tumors from patients, but not in 
the corresponding normal tissues [353], suggesting that these complex formations might have 
significant roles in cancer. ΔNp73 protein isoforms act in a dominant negative fashion over 
functions of TAp73 and p53 proteins and inhibit their transcriptional activities. ΔNp73 protein 
isoforms also inhibit both TAp73- and p53-mediated apoptosis [11, 353]. 
p63
+/−
 p73
+/−
 double heterozygous mice have been shown to have a shorter life span than p63
+/−
 or 
p73
+/−
 mice [100, 226]. p63
+/−
 p73
+/−
 double heterozygous mice develop spontaneous tumors and 
malignant tumors at a higher frequency as compared to p63
+/−
 or p73
+/−
 mice. Interestingly, more 
aggressive tumor phenotypes (higher tumor burden and metastases) and shorter life spans are 
noticed in p53
+/− 
p73
+/− 
and p53
+/−
 p63
+/−
 mice than in p53
+/− 
mice [100, 226].  
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4. p73 
Transcription factors regulate transcription of gene promoters and they also participate in cellular 
signaling networks. Among these transcription factors one of the well-studied is p53. p73 is a 
structural and functional homologue of p53, and transcriptionally regulates various biological 
processes.  
 
4.1. Transcriptional activities of p73 
Transcription factors are proteins and they recognize specific DNA sequences within 
promoter/enhancer regions of their target genes with their DBD. p73 transcriptionally regulates 
various genes involved in development, differentiation, cell cycle and apoptosis. p73 is active as a 
homotetramer. However, it can form heterotetramers with p63 [141]. It recognizes p53REs within 
the promoter/enhancer regions of various genes [91]. TAD of p73 is responsible for transactivation 
of its target genes. Our group identified a second TAD at the carboxy-terminal region of p73 that is 
located within amino acid residues 381-399 [236, 304]. 
p73 isoforms can bind to p53 REs and transcriptionally activate a subset of p53-target genes, which 
induce cell cycle arrest, apoptosis, and senescence in a p53-like manner [145, 146, 149]. In 2005, 
Zhu et al., described that the same gene can be differentially transactivated by different isoforms of 
p73 [362]. Description of some genes that are differentially regulated by p73α and p73β are 
presented in Table 1. 
 
Genes regulated by  
p73 isoforms 
Fold increase in relative mRNA expression 
levels with respective p73 isoform 
p73α p73β 
P21 17,5 3,2 
MDM2 14,8 1,4 
GADD45 4,3 1,5 
BAX 3,6 0,8 
14-3-3σ 3 17 
 
Table 1. Differential induction of cellular targets by p73α and p73β [362]. 
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Our group identified that TAp73α, but not TAp73β induces the expression of anti-apoptotic Hsp72 
protein in SCLC cells. We also reported that in several cell lines p57
Kip2 
protein expression is 
induced by TAp73β, but not by TAp73α. Furthermore, our group found that co-expression of p53 
with DBDmut p73α (a R268Q, R300C mutant of p73) promotes nuclear localization of DBDmut 
p73α protein. Increased nuclear localization of DBDmut p73α by p53 seems to promote the 
recruitment of DBDmut p73α at the P21 gene promoter and thereby inducing its transactivation. 
Association of p73 with other proteins and its posttranslational modifications appears to influences 
its transcriptional activities [59, 197, 215, 297, 355]. 
 
4.2. Role of p73 in development 
Gene expression is carefully regulated during embryonic development. Temporal and spatial control 
of gene expression is monitored by several mechanisms such as lionization (X-chromosome 
inactivation), epigenetic modifications, TF-dependent transcription and mRNA splicing. Thousands 
of proteins carefully coordinate with each other during all stages development of a living organism. 
The interactions between these proteins and their temporal expression are important for its proper 
development. p73 is one of the proteins that plays important roles in development. p73 isoforms 
seem to play a role in the terminal differentiation of human skin keratinocytes [215]. The loricrin 
and involucrin genes are induced during the keratinocyte differentiation and they are recognized as 
molecular markers of epidermal differentiation [253]. p73γ and p73δ transactivates loricrin and 
involucrin gene promoters [68], suggesting a role of p73 in keratinocyte development.  
Downregulation of the N-Myc proto-oncogene [310] and upregulation of the Rb tumor suppressor 
[67, 256] are reported during differentiation of neuroblastoma cells in vitro. In N1E-115 murine 
neuroblastoma cells, decrease of N-Myc levels and increase of the pRB levels are noticed upon 
overexpression of p73β [67], suggesting that p73β might be involved in neuroblastoma 
differentiation. p73 is accumulated during the murine neuroblastoma cell differentiation induced by 
retinoic acid treatment [67], further supporting that it might play an important role in differentiation. 
Withdrawal of NGF induces apoptosis in sympathetic neurons of mice and it has been shown that 
ectopic expression of either ΔNp73α or ΔNp73β protects sympathetic neurons from NGF depletion 
induced apoptosis [250]. Moreover, ΔNp73β interacts with p53 and inhibits p53-induced neuronal 
apoptosis during development of the mouse nervous system [215, 250], collectively suggesting that 
ΔNp73β is important for the survival of neurons. ΔN isoforms are predominantly expressed during 
development of the brain [336] suggesting that p73 expression might be important for normal 
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neuronal development. In support of this idea, ΔNp73-/- mice were shown to have a reduced 
neuronal density in the brain [336]. p73 null mice show central nervous system defects and 
pheromone abnormalities, hippocampal dysgenesis with aberrant lower blade of the DG (dentate 
gyrus), loss of CR (Cajal-Retzius) cells, hydrocephalus and abnormalities in the limbic 
telencephalon. Moreover, P73
-/-
 mice are infertile due to defects in early embryonic development 
[312], and a majority of p73 knockout mice die at an early stage due to chronic infections [346].  
 
4.3. Regulation of p73 expression and its activity 
Activity and function of a protein is influenced by factors such as its level of expression, post-
transcriptional modifications and interactions with other proteins. p73 is expressed differently in 
different cells depending on the stage of life. Deregulation of p73 can alter its transcriptional 
activities on genes involved in biological processes and also its participation in cellular signaling 
networks. p73 expression, activity and function are regulated at four different levels. 
 
4.3.1. Transcription of P73  
Transcriptional regulation of the P73 gene is important to maintain its proper cellular levels. In 
several cancers, altered levels of p73 expression were identified and low or high levels of p73 can 
significantly alter the biological activities regulated. Stimuli, such as DNA damage [49], viral 
factors [39] and transcriptional regulators [102, 172] can regulate P73 gene expression at the 
transcriptional level. A regulatory 1 kb stretch of the intron 1 region upstream of the initiating ATG 
codon in exon 2 of P73, contains six binding sites for the transcriptional repressor ZEB1 (δEF1). 
Inhibition of ZEB1 (δEF1) increases p73 expression [102]. p1 and p2 promoters of P73 are located 
within exon 1 and intron 3, respectively. Upstream of and within the p1 promoter lies putative 
binding sites for transcriptional regulators like Sp1, E2F, AP-2 and Egr-1,-2,-3 [81]. The p1 
promoter of P73 contains three E2F, a transcription factor family, binding sites and in vitro binding 
of E2F1 to two of these binding sites mediates an increased expression of TAp73 transcripts [268, 
282]. Early growth response factor-1(Egr-1) is one of the rapidly induced early response genes to 
various environmental signals [344]. Egr-1transactivates the p1 promoter, but not the p2 promoter 
of the P73 gene [350]. The adenovirus early region 1A (E1A) also transactivates its p1 promoter, 
but not the p2 promoter [99]. E2F1, c-Myc, and E1A induces expression of full-length p73α and 
p73β [352].  
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Much less is known about transcriptional regulation of the p2 promoter. This promoter contains a 
p53 RE [114] and is transcriptionally regulated by both p53 [153, 326] and TAp73 [223]. ΔNp73 
physically interacts with TAp73 and p53, and regulates their functions by blocking their 
transcriptional activity thus mediating a dominant negative feedback loop [223].  
Loss of p73 mRNA expression is noticed due to hypermethylation (a histone mark for gene 
silencing) of P73 in hematological malignancies like acute lymphoblastic leukemia (ALL) and 
Burkitt’s lymphomas [58]. P73 was also found hypermethylated in 94 % of natural killer (NK) cell 
lymphomas [29], suggesting an epigenetic regulation of p73 expression.  
 
 
4.3.2. Post-transcriptional modifications of p73 mRNA 
As mentioned earlier, as a result of alternative splicing, the p73 primary transcripts generated form  
the alternative promoters can be expressed as various carboxy- and amino-terminal variants (refer to 
Figure 4A.). The p1 and p2 promoters of the P73 gene encode amino-terminal TAp73 and ΔNp73 
isoforms, respectively. p2 promoter generates, two mRNAs (ΔNp73 and ΔN′p73)  differing  in their 
3′-untranslated region by two-way usage of exon 3′. However, they encode an identical ΔNp73 
protein, which lacks the amino-terminal transactivation domain found in TAp73 proteins [136]. 
p73Δex2 and p73Δex2/3 5´-terminal spliced transcripts are also detected in several human tumor 
cells [289]. Expression of p73Δex2, a 5´-terminal spliced variant of p73 transcript with the deletion 
of exon 2 was detected in the ovarian tumor cell lines, but not in the human normal ovarian surface 
epithelial (HOSE) primary cultures [227]. Deletion of exon 2 would delete the first 48 amino acid 
residues at amino-terminal region as compared to the full-length TAp73. In hepatocellular 
carcinomas, aberrant spliced p73 variants i.e., p73Δex2, p73Δex2/3 that do not contain exon 2, and 
exon 2 and 3, respectively have been identified [291]. 
Among the p73 variants, TAp73α is the longest isoform and contains all 14 exons. Carboxy-
terminal β ,γ, δ, ζ, and ε isoforms do not contain the exon 13, exon 11, exons 11–13, exons 11 and 
12, and exons 11 and 13, respectively [136].  Ishimoto O et al., reported that among 33 tested 
human tissue, the ΔN′p73 transcript was only detected in the pancreas and the ΔNp73 transcript was 
only detected in fetal lung and corpus callosum among eight sub regions of the brain.  p73α 
expression was identified in a variety of human tissue like, brain, pancreas, testis, prostate and 
cerebellum,  whereas p73β expression was identified in lymph nodes, spinal cord and cerebellum. 
p73γ expression was detected  in liver, small intestine, fetal lung, and cerebellum (for further 
details, refer to  [136]).   
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Expression of  p73η, which lacks the exons 10-13, was detected in neuroblastoma and in the MCF-7 
breast carcinoma cell line [279]. Its expression was not detected in B-lymphocytes from seven 
healthy donors. The p73η´ is generated from splicing of two nucleotides at 3´end of exon 9 and 
complete splicing of exons 10-12, whereas the last 18 nucleotides of exon 13 are retained. In p73θ, 
exons 10, 11 and 13 are completely spliced out, but the exon 12 is retained. In contrast to the p73η, 
p73η´ and p7θ isoforms have been also identified in non-tumor lymphocytes. 
Although p73 can be expressed as 45 different putative isoforms (refer to Figure 4B.), to my 
knowledge, no human tissue or cell line is yet identified that expresses all of these isoforms. 
Expression of p73 spliced variants seems to be regulated by the tissue-specific mRNA splicing 
mechanisms. 
 
4.3.3. Post-translational modifications of p73 
Post-translational modifications are the chemical modification of one or several amino acids of 
a protein. Functions of a protein can be greatly influenced by the modification of functional groups, 
such as acetate, phosphate, lipids and carbohydrates, of its amino acids. These modifications can be 
reversible and influence the structure, function, stability, localization and activity of a protein. 
 
c-abl, a non-receptor tyrosine kinase, phosphorylates TAp73α/β and ΔNp73α/β and stabilizes them. 
c-abl phosphorylates TAp73α on tyrosine (Tyr)-99, and to a lesser extent on Tyr-121 and Tyr-240 
[1, 315, 351], and its kinase activity is required for pro-apoptotic activity of p73 [1]. c-Jun N-
terminal kinase (JNK) physically interacts with and phosphorylates p73. JNK-mediated 
phosphorylation promotes p73 transcriptional activity on growth arrest and DNA damage 45 
(GADD45) and BAX gene promoters [143]. p300, a histone acetyltransferase (HAT), acetylates 
p73α after DNA damage, and inhibition of p300 by Lys-CoA decreases apoptosis induced by p73α 
[59].  
Protein inhibitor of activated STAT-1(PIAS-1) binds and sumoylates p73α and stabilizes it. This 
sumoylation leads to the inability of p73α to transactivate BAX and P21 gene promoters. PIAS-1 
expression starts at the end of the G1 phase, peaks during the S phase, and completely disappears in 
the G2 phase of the cell cycle. This PIAS-1-induced p73-mediated inhibition of p21 expression 
seems to facilitate G1/S transition [217]. 
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4.3.4. Interactions of p73 with various proteins and its degradation 
As mentioned earlier, protein-protein interactions regulate activity and stability of a protein. 
Various proteins interact with p73 and post-transcriptionally modify it, thereby influencing its 
stability and biological functions. 
ΔNp73 physically interacts with p73 and p53 and inhibits their pro-apoptotic functions [224]. The 
p53 inhibitor Mdm2 interacts with p73α. However, in contrast to Mdm2-p53 interaction, Mdm2 
interaction with p73α does not promote its degradation, but inhibits its transcriptional activity [42, 
354]. Interestingly, p73 transactivates MDM2 promoter [171, 327, 362], suggesting that a feedback 
regulatory loop exists in the p73-Mdm2 signaling network. In this network, Mdm2 blocks the 
transcriptional activity of p73, but does not affect its levels. p300 and cAMP response element-
binding protein-binding protein (CBP) binds to p73α and enhances its transcriptional activity, thus 
act as transcriptional co-activators. Moreover, p300, a transcriptional co-activator enhances the 
apoptotic function of p73α [355]. Both Mdm2 and p300/CBP bind to the amino-terminal region of 
p73. The interaction of Mdm2 with p73 blocks the p73-p300/CBP interactions. This might be a 
reason for the transcriptional inactivation of p73 by Mdm2 [354]. c-Myc, a proto-oncogene protein, 
physically interacts with p73α and inhibits p73α-mediated transcriptional activation of P21 and 
BAX gene promoters [330]. Yes associated protein (Yap) interacts with p73 and enhances its 
transcriptional activity on the BAX promoter [296]. Human Papillomavirus (HPV)-E6 protein 
associates with p73 and inhibits its ability to transactivate the P21 gene promoter [245]. Protein 
interacting with ‘‘never in mitosis A (NIMA) 1’’ (Pin1), a prolyl isomerase, stabilizes p73 by 
physically interacting with it. Pin1 is required for p73 to transactivate genes involved in apoptosis 
[197]. c-Abl interacts with p73 via SH3 (Scr-homology-3) domain and phosphorylates it. 
Phosphorylation of p73 by c-abl stabilizes p73 protein and enhances its apoptotic function [110]. 
 
Proteolysis is the process of breakdown of proteins into smaller polypeptides or amino acids. Some 
enzymes, i.e. proteases, hydrolyse peptide bonds to degrade proteins. p73 degradation is regulated, 
in part, by the ubiquitin proteasome system, which is a sophisticated cellular proteolytic machinery 
in many eukaryotic cells [42, 109, 156, 165]. Promyelocytic leukemia (PML) protein physically 
interacts with p73, and promotes p300-mediated acetylation as well as stabilization of p73. PML 
reduces ubiquitinylation levels of p73, thereby protecting it from the ubiquitin proteasome system-
mediated degradation [20]. Pirh2, a p53 regulated RING finger E3 ubiquitin ligase, physically 
interacts with p73. Pirh2 polyubiquitinates p73, thereby promoting its ubiquitin proteasome 
mediated degradation [147].  
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The degradation of p73 seems to be isoform-dependent, for example, upon DNA damage, ∆Np73 is 
degraded more rapidly than TAp73 [195, 267, 324]. TAp73α induces the expression of PIR2, a ring 
finger domain ubiquitin ligase p73-induced RING 2 protein that differently regulates the stability of 
TAp73 and ΔNp73 isoforms. Co-expression of PIR2 and TAp73α results in an increase in TAp73α 
protein levels, whereas co-expression of PIR2 and ΔNp73α results in a decrease in ΔNp73α levels. 
This suggests that PIR2 differently regulates TAp73 and ΔNp73 protein levels [277]. p73α and 
p73β undergo differential degradation by the proteasome, where p73α is sensitive and p73β is not 
sensitive to this degradation [212]. p73α, but not p73β, is covalently sumoylated by the small 
ubiquitin-like modifier-1 (SUMO-1) on lysine residue 627. Although SUMO-1-mediated 
modification is not absolutely required for degradation of p73, sumoylated p73 is more rapidly 
degraded by the proteasome than unmodified p73 [212].  
 
 
5. Apoptosis 
Cell death mechanisms like anoikis, necrosis, autophagy and apoptosis play important roles in 
maintaining the tissue homeostasis. These cell death mechanisms are important for regulating 
development, cell growth, immune response and clearing of redundant or unnecessary cells [93]. 
Apoptosis is a well-studied cell death mechanism in which cell blebbing, shrinkage, and 
fragmentation of chromosomal DNA and nuclei takes place. Billions of cells die by apoptosis in the 
human body every day, just to keep balance with the numbers of new cells generated from the 
body's stem cell populations [121, 259]. 
 
5.1. Morphological and Biochemical features of an apoptotic cell 
During the process of apoptosis a lot of biochemical and morphological changes occur in the 
apoptotic cell. Caspases, a family of cysteine and aspartic proteases, are activated. They play a 
major role in execution of apoptosis by cleaving and/or activating several substrates, for example, 
endonucleases, nuclear lamins, PARP (poly-ADP ribose polymerase), PAK2 (p21-activated kinase 
2). Subsequently, the apoptotic cell loses microvilli and desmosomes, and then loses contact with 
the surface or adjacent cells. Activated endonucleases cleave nuclear DNA into internucleosomal 
fragments. Thus, DNA ladder pattern formation upon regular agarose gel electrophoresis can be 
identified. The plasma membrane extends and seals the detached solid cellular material into vesicles 
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named ‘‘apoptotic bodies’’. These apoptotic bodies are packed with densely crowded cellular 
organelles and fragments of the nucleus. 
Ladder pattern of DNA fragmentation, caspases activation and apoptotic body formations are key 
features of an apoptotic cell death. In the immune system well developed organisms, such as 
humans and mice, phagocytes accumulate at the site where apoptotic cells are located. They 
recognize the apoptotic cells through receptors and engulf them. Engulfed apoptotic cells are then 
processed within the phagocytes [89], thus no signs of inflammation are noticed.  
 
5.2. Stimuli that initiate apoptosis 
The process of apoptosis can be initiated by stimuli like DNA damage (e.g. caused by ionizing 
radiation and alkylating agents), cell membrane damage (e.g. caused by UV light, oxidizing agents 
and heat) and stimuli that activate death receptors (e.g. Tumor necrosis factor-α and Fas ligand) 
 
5.3. Proteins and Organelles involved in regulation of apoptosis 
The apoptotic process is regulated by a variety of proteins and organelles. However, their roles in 
the regulation of apoptosis are still not fully understood.  
 
5.3.1. Caspases 
Caspases play important roles in initiation and execution of apoptosis and inflammation. They are 
expressed as pro-enzymes (zymogens) in the cell. Upon proper stimuli, caspases are processed and 
activated. To date, 14 caspases have been identified and they are involved in inflammatory 
responses (e.g. caspase-1, -4, -5 and -12) or apoptosis. The caspases that are involved in apoptosis 
are classified as initiator caspases (caspase-2, -8, -9 and -10) or effector caspases (caspase-3, -6 and 
-7) [5]. 
 
 Processing and activation of caspases are regulated by a number of molecules, such as inhibitor of 
apoptosis protein (IAP), fas-associated death domain (FADD), apoptotic protease activating factor-
1 (Apaf-1), Bcl-2 family members and FADD-like interleukin-1beta-converting 
enzyme (FLICE) inhibitory protein (FLIP) [86]. Overexpression of pro-apoptotic caspases induces 
apoptosis in various cell lines. For example, overexpression of caspase-2 induces apoptosis in small 
cell lung carcinoma (SCLC) cells [218]. Active caspase-2 cleaves full-length Bid to active Bid (also 
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known as truncated Bid or tBid). tBid activates Bax, thereby promoting the release of pro-apoptotic 
proteins from mitochondria. Overexpression of caspase-2 promotes translocation of Bax to the 
mitochondria, thereby inducing mitochondria-mediated apoptotic cascade [28, 118, 170, 193]. 
 
5.3.2. Heat shock proteins 
Heat shock proteins (Hsps) were discovered in the larvae of Drosophila melanogaster after 
exposing them to heat shock [166]. Their levels are also elevated under other types of stress stimuli. 
Hsps are encoded by the HSP70 and HSP90 gene families. Molecular weights of Hsps range from 
~
15 to 110 kDa. Based on their function and molecular weights they are divided into several groups 
(for more details, refer to [126, 333]). Hsps are localized in different compartments of the cell, like 
cytosol, mitochondria, endoplasmic reticulum (ER) and nucleus. They are involved in the 
maintenance of protein structures, refolding of misfolded proteins, prevention of protein 
aggregation and the degradation of unstable proteins [40, 51, 76, 214, 242].  
Hsps also play key roles in the regulation of apoptosis. Hsp27, -70, and -90 proteins function as 
anti-apoptotic, whereas Hsp60 functions as pro-apoptotic proteins. They act at multiple levels of the 
apoptotic signalling pathway [80], for example, HSPA1A/Hsp72/Hsp70–1 (referred to later as 
Hsp72) inhibits lysosomal membrane permeabilization, thereby inhibiting the release of cathepsins 
and other proteases, which are involved in the apoptotic signaling pathway [23, 119]. In addition, 
Hsp72 inhibits the apoptotic cascade by inhibiting JNK, preventing the translocation of Bax to the 
mitochondria [183], by interacting with apoptosis-inducing factor (AIF) and Apaf-1 [271], and by 
inhibiting the processing of caspase-9 and -3 [16]. 
 
5.3.3. The Bcl-2 family of proteins 
Bcl-2 family proteins are prime regulators of the intrinsic apoptotic pathway and govern 
mitochondrial outer membrane permeabilization (MOMP). Bcl-2 homology (BH) domains are 
characteristic features of the Bcl-2 family proteins, which share one or more of the four BH 
domains (i.e. BH1-4). Bcl-2 family members are categorized as anti- or pro-apoptotic proteins. The 
anti-apoptotic proteins (e.g. Bcl-2, Bcl-XL, Mcl- 1, A1 and Bcl-W) contain all four BH (BH1,-2,-3 
and -4) domains and a carboxy-terminal transmembrane (TM) domain. The pro-apoptotic family 
members (e.g. Bax, Bak and Bok) contain the TM domain and BH1,-2 and -3, but not BH4. Other  
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Figure 5. Structure of the Bcl-2 family of proteins. The Bcl-2 family proteins are key regulators of the 
intrinsic apoptotic pathway and govern mitochondrial transmembrane potential and subsequent release of the 
cytochrome c (Cyt c). Members of the Bcl-2 family contain characteristic Bcl-2 homology (BH) domains. 
The anti-apoptotic Bcl-2 family members contain all four BH (i.e. BH1-4) domains and their overexpression 
inhibits apoptosis. They prevent BH3-only proteins induced oligomerization of the pro-apoptotic Bcl-2 
family members, for example, Bax/Bak in the mitochondrial outer membrane. Most of anti-apoptotic Bcl-2 
family members contain transmembrane (TM) domains thus they are typically associated with membranes. 
The pro-apoptotic Bcl-2 family members promote apoptosis by forming pores in the outer mitochondrial 
membrane. The BH3-only subfamily of pro-apoptotic Bcl-2 family members contains only BH-3 domain 
and/or TM. The mammalian BH3-only protein family contains eight members (Bid, Bad, Bim, Bik, Bmf, 
Noxa, Puma and Hrk) and upon overexpression they promote apoptosis. Bid is activated via proteolysis 
mediated by caspase-8 and active Bid (i.e. tBid) activates Bax/Bak and induces releases of Cyt c [60, 75, 
124, 157, 308]. 
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pro-apoptotic proteins of the Bcl-2 family contain the BH3 domain and TM (e.g. Bik and Bnip) or 
only the BH3 domain (e.g. Bad, Bid, Bim and Egl-1). 
 
Bcl-2 family members can form homo- or heterodimers among themselves [41]. Anti-apoptotic Bcl-
2 proteins are mostly found in membranes of the ER, mitochondria and the nucleus. Most pro-
apoptotic Bcl-2 family proteins are localized in the cytosol. Upon initiation of the death cascade, 
pro-apoptotic Bcl-2 family proteins undergo conformational changes and integrate into the outer 
mitochondrial membrane, and promote loss of mitochondrial transmembrane potential [90, 115, 
167, 339].  
 
Bax is a globular protein that consists of nine α helices [300]. It is a soluble protein located in the 
cytosol. The amino-terminal part of the Bax protein (i.e. amino acid residues 20-37) contains a 
mitochondrial targeting sequence, and deletion of this sequence results in the termination of its 
mitochondrial localization ability [46]. During the process of apoptosis Bax undergoes 
conformational changes and translocates to the mitochondria [339], subsequently mitochondria lose 
their transmembrane potential [168]. Cleavage of Bid by caspase-8 leads to its activation [107, 
182]. Cleaved active carboxy-terminal fragment of Bid (i.e. tBid), translocates to the mitochondria. 
tBid activates Bax/Bak proteins, thereby promoting MOMP [75, 157].  
 
Overexpression of anti-apoptotic Bcl-2 protein decreases the pro-apoptotic responses of irradiation 
and chemotherapy [152], whereas overexpression of pro-apoptotic proteins, e.g. Noxa, Puma and 
Bax, promotes drug-induced apoptosis [184, 360]. Del Poeta et al., reported that the ratio between 
Bax and Bcl-2 (pro- and anti-apoptotic proteins, respectively) influences both a longer overall 
survival (OS) and disease-free survival (DFS) in acute myeloid leukemia (AML) [71].  
 
Two models exist, which explain the roles of BH-3 only proteins in promoting apoptosis. The first 
model is called the ‘‘direct activation model’’, in which BH-3 only proteins bind to Bax or Bak, and 
induce their conformational change, which leads to their activation. The second model is called the 
‘‘neutralization model’’, in which pro-apoptotic BH-3 only proteins bind and inactivate the anti-
apoptotic Bcl-2 family of proteins like Bcl-XL and Bcl-2 [50]. 
 
According to ‘‘The rheostat model’’ proposed by Korsmeyer et al., formation of heterodimers and 
the balance between the pro- and anti-apoptotic proteins of the Bcl-2 family creates a life or death 
switch for a cell. This model suggests that pro- and anti-apoptotic proteins directly counterbalance 
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each other functions, where more abundant protein regulate whether the cell dies or survives [163]. 
According to a model proposed by Edlich et al., Bax is constantly translocated to the mitochondria 
in healthy cells, where anti-apoptotic Bcl-2 family members, e.g. Bcl-XL, bind to Bax and 
retranslocate it into the cytoplasm. Blocking of anti-apoptotic Bcl-2 proteins by BH3-only proteins, 
e.g. Bim, results in Bax accumulation on the mitochondria [84].  
 
 
5.3.4. Mitochondria 
Mitochondria are membrane bound organelles that produce ATP (adenosine 5’-triphosphate). They 
are found in eukaryotes and have been described as ‘‘the energy power house of the cell’’ [202]. 
Apart from their role in generation of energy and well established role in the induction of apoptosis 
[113, 139], they are also involved in cellular processes such as differentiation [73], cell cycle [97, 
240], cell growth [94] and cell signaling [302]. 
  
Pro-apoptotic Bcl-2 family proteins regulate the release of pro-apoptotic proteins from the 
mitochondria. During the process of apoptosis, one or several of the BH3-only proteins (Bad, Bid, 
Bik, Bim, Bmf, Hrk, Nix, Noxa, Bnip3 and Puma) undergo activation and directly or indirectly 
activate Bax and/or Bak. For example, tBid, Bim and Puma directly bind and activate Bax and Bak. 
Active Bax and Bak induce the loss of mitochondrial transmembrane potential (LMMP). As a result 
pro-apoptotic mitochondrial proteins like Cyt c, second mitochondrial activator of caspases/direct 
inhibitor of apoptosis proteins (IAP) binding protein with low pl (Smac/Diablo), AIF and 
endonuclease G (Endo G) are released into the cytosol.  
 
5.3.5. The Cip/Kip family of proteins  
Cyclin-dependent kinase (CDK) inhibitors (CKI’s) bind and inhibit the activity Cyclin/CDK 
complexes, which promote cell proliferation [57] to prevent abnormal cell proliferation [283, 284]. 
To date, seven CKI’s have been identified in mammals and they are classified into two families 
according to their structural and functional similarities [225]. The Cip/Kip (CDK interacting 
protein/kinase inhibitor protein) family comprises p21
Cip1
 (also called Waf1, Sdi1, or CAP20 and 
later it is referred to as p21 ), p27
Kip1
 and p57
Kip2
 [225]. These three members have a conserved 
cyclin-dependent kinase binding/inhibitory domain at its amino-terminal region. The other family, 
designated Ink4, comprises p16(INK4a), p15(INK4b), p18(INK4c) and p19(INK4d) [62]. These 
family members have four ankyrin motif tandem repeats in common. The Ink4 family of proteins 
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inhibits the activity of CDK4 or CDK6 specifically, whereas the Cip/Kip family of proteins shows a 
broad spectrum of inhibitory effects on cyclin/CDK complexes [74]. 
p21 is induced by various stress stimuli, and its induction may cause cell cycle arrest. 
Overexpression of p21 results in cell cycle arrest [108]. p21 plays an important role in preventing 
tumor development by suppressing tumor growth in vitro and in vivo [108]. Mice lacking p21 are 
more susceptible to chemically induced skin carcinoma [246, 314]. p21 holds pro-apoptotic 
functions and its overexpression promotes the drug-induced apoptotic response in a variety of cell 
lines [162, 187]. p21 overexpression induces apoptosis in xenografts of human cervical cancer cells 
[316].  
 
p57
Kip2 
expression promotes drug-induced apoptosis in several cell lines [273, 325]. p73β-induced 
apoptosis was reduced after inhibition of p57
Kip2 
by siRNA, suggesting that p57
Kip2 
mediates the 
apoptosis [112]. These observations indicate roles of the p57
Kip2 
during apoptosis. However, the 
precise mechanisms of p57
Kip2 
in apoptosis are still unclear. On the other hand, some studies have 
also shown anti-apoptotic roles for p21 [9, 131] and p57
Kip2 
[47]. 
 
5.3.6. Lysosomes  
Lysosomes are acidic, single-membrane bound organelles present in eukaryotic cells. They are also 
called the suicide bags of the cells. They contain several acid hydrolases, including phosphatases, 
nucleases, glycosidases and proteases [12]. Of the lysosomal proteases, the cathepsin family is well 
characterized. According to the amino acids of their active sites that confer catalytic activity, the 
cathepsins are subdivided into cysteine (cathepsin B, C, F, H, K, L, O, S, V, W, and X), serine 
(cathepsin A and G) and aspartic (cathepsin D and E) cathepsins [356]. 
A wide range of apoptotic stimuli, such as death receptor activation, oxidative stress, DNA damage 
and growth factor starvation [38, 95, 160, 293], can induce lysosomal destabilization, which will 
later be referred to as lysosomal membrane permeabilization (LMP). For many years, lysosomes 
were thought to be mainly involved in necrotic and autophagic cell death. Accumulating evidences 
are indicating that partial lysosomal membrane permeabilization (LMP) and consequent release of 
lysosomal proteases into the cytosol may initiate or execute the apoptotic cell death [117, 173, 293, 
318, 319]. Partial or selective lysosomal permeabilization can lead to release of other hydrolases, 
H
+
 (causing acidification of the cytosol) and Ca
2+
 into the cytosol during onset of apoptosis [43]. 
The lysosome-mediated apoptotic pathway can be activated by death receptors, lipid mediators and 
photodamage [117]. In some circumstances LMP is an early event and essential for apoptosis 
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signaling to proceed, while under other circumstances LMP occurs at a late stage of the cell death 
process that amplifies the death signals [142]. 
 
Microinjection of cathepsins into the cytosol initiates apoptotic cell death [24, 262, 280]. Disruption 
of lysosomal membrane results in the release of cathepsins (e.g. cathepsin D, cathepsin B and L ) 
into the cytosol. Once in the cytosol, they activate Bid, degrade the anti-apoptotic Bcl-2 protein and 
X-linked inhibitor of apoptosis (XIAP), thereby initiating the apoptotic cascade [38, 53, 160, 320]. 
This results in Cyt c release from mitochondria and activation of caspases. In activated human T 
lymphocytes, upon staurosporine treatment, cathepsin D, which is released from the lysosomes, 
induces Bax activation independent of Bid cleavage. This results in mild outer mitochondrial 
membrane permeabilization, a result limited to AIF release [22].  
 
5.4. Apoptotic pathways 
Apoptosis can be triggered by various stimuli, which can initiate either of the two following 
apoptotic signalling pathways. 
 
5.4.1. Extrinsic pathway 
Members of the tumor necrosis factor (TNF) receptor superfamily are popularly known as ‘‘death 
receptors’’. These death receptors contain cysteine rich extracellular domains and a cytoplasmic 
domain, the “death domain (DD)’’ [10]. These death receptors are involved in transmitting the 
extracellular death signals to the intracellular apoptotic signalling cascade. Transmembrane death 
receptor and death signal interactions initiate the extrinsic apoptotic pathway. Stimulation of these 
death receptors by corresponding ligands results in the cytosolic recruitment of an adapter molecule 
named FADD through the interaction between DDs. Thereafter, FADD recruits DED (death 
effector domain)-containing procaspase-8 through DED/DED interactions, thus forming the death 
inducing signalling complex (DISC) [52, 204]. Formation of DISC facilitates the autocatalysis of 
procaspase-8 and thereby its activation [359]. 
Cellular-FLIP (c-FLIP), an anti-apoptotic regulator, binds to FADD and/or caspase-8 and 
negatively regulates their activities. c-FLIP prevents the DISC formation, thereby inhibiting the 
extrinsic apoptotic cascade [269]. 
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5.4.2. Intrinsic pathway 
Diverse non-receptor-mediated stimuli such as radiation, hypoxia, hyperthermia, toxins, viral 
infections, and free radicals can induce LMMP [88]. LMMP results in the release of pro-apoptotic 
factors (e.g. Cyt c, AIF, Endo G and Smac/Diablo) into the cytosol from the mitochondria. Released 
Cyt c takes part in the formation of the apoptosome, which is composed of Cyt c, Apaf-1 and 
procaspase-9. Apoptosome formation facilitates activation of caspase-9, which is involved in the 
further processing and activation of other caspases, like caspase-3 and -7 [201].  
IAPs are a family of anti-apoptotic proteins. IAPs can bind and inhibit the activity of caspases, 
thereby inhibiting the apoptotic cascade. When Smac/Diablo is released from the mitochondria, 
they interact with IAPs and antagonizes them, thereby facilitating the activation of caspases [201].  
 
5.4.3. Execution phase of extrinsic and intrinsic apoptotic pathways 
The extrinsic and intrinsic apoptotic pathways leads to the execution phase of the apoptotic 
pathway, in which “effector/executioner” caspases (caspase-3, -6, and -7) play key roles. Caspase-3 
can process and activate many substrate proteins including endonucleases, e.g. inhibitor caspase-
activated DNase (ICAD). Cleavage of ICAD results in the release of caspase-activated DNase 
(CAD). Released CAD translocates into the nucleus where it cleaves DNA into internucleosomal 
fragments [306]. Active caspase-3 and -7 cleave and/or activate several substrates such as cytosolic 
endonucleases and proteases, e.g. PARP [33], cytokeratins, cytoskeletal protein fodrin [198], and 
nuclear protein NuMA (nuclear mitotic apparatus protein) [301]. These activated cellular 
components are involved in the degradation of the nucleic acids and cytoskeletal proteins.  
AIF and Endo G are released from the mitochondria after LMMP and they have nuclease activity. 
They can directly translocate into the nucleus and participate in nuclear fragmentation. These series 
of events lead to the morphological and biochemical changes seen in the apoptotic cells [88, 286]. 
LMMP can occur due to various stimuli and LMMP results in the release of Cyt c from the 
mitochondria. Cyt c couples with Apaf-1 and procaspase-9 to form the apoptosome, which 
facilitates activation of procaspase-9. IAPs prevent the activation of caspases. Smac/Diablo released 
from the mitochondria blocks the activity of IAPs, thereby promoting activation of caspases. 
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Figure 6. An overview of the extrinsic and intrinsic pathways of apoptosis. Initiation of apoptosis can 
lead to the activation of any of the two apoptotic pathways, extrinsic or intrinsic pathway. The death receptor 
activated extrinsic pathway is mediated by caspase-8, whereas the intrinsic pathway is mediated by caspase-
9. In the extrinsic pathway, activation of the death receptor leads to the recruitment of an adaptor molecule 
named FADD to its cytosolic DD. Then FADD couples cytosolic DD of death receptors to procaspase-8. 
This promotes the autocatalysis and activation of caspases-8. cFLIP, an inhibitory protein, prevents caspase-
8 activation.  
Crosstalk between the two apoptotic pathways occurs via caspase-8-mediated cleavage and 
activation of Bid. Activated Bid further activates Bax, thereby engaging the mitochondria-mediated 
intrinsic pathway. Similarly, caspase-3, which is activated in the intrinsic pathway, cleaves and 
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activates procaspase-8, thereby initiating the activation of components of the extrinsic pathway [17, 
128, 129]. 
 
5.5. Role of apoptosis in diseases 
Abnormalities in the apoptotic process have a significant role in the progression or regression of 
diseases. Increased apoptosis can cause neurodegenerative diseases, e.g. Alzheimer’s disease, 
Parkinson’s disease, Huntington disease [275], as well as myelodysplastic syndromes [238] and 
acute myocardial infarction [238]. Decreased apoptosis is noticed in autoimmune disorders, in viral 
infections like, Herpes viruses and Adenoviruses, and in various cancers [150]. 
 
 
6. Role of p73 in cell life and death decisions 
Transcriptional dependent and independent activities of p73 play important roles in regulation of 
cell life and death decisions. Regulation of cell life and death decisions by p73 appears to have 
significant impact on development and cancer treatments. 
 
6.1. Role of p73 in cell life 
Billions of cells are generated and simultaneously died during various stages of human 
development. Cell death is important for sculpturing various parts of the body, for example, in 
formation of joints and separation of fingers. Cell death has to be carefully regulated for the proper 
morphogenesis of an organism. An increase in the cell death than required level can cause abnormal 
organ formation and various diseases. 
 
p73 protects the cells from cell death in a variety of situations. In cultured cortical neurons of mice, 
a decrease in the number of wild-type P73 alleles caused an increase in JNK activity, which 
promotes apoptotic signalling. Release of lactate dehydrogenase (LDH) into the medium is a 
biochemical indicator of necrosis. In these cells, a decrease in the P73 copy number increased 
the release of LDH into the medium [32, 77, 335].  
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ΔNp73 inhibits TAp73α-, TAp73β- and TAp73γ-induced transactivation of pro-apoptotic Cluster of 
differentiation 95 (CD95) [220] and BAX [220, 224] gene promoters, and thereby confers 
chemoresistance [220, 266]. ΔNp73 interacts with p73α and it inhibits p73α-induced neuronal cell 
death in a dose-dependent manner [223]. ΔNp73β physically interacts with p53 and increased 
expression of ΔNp73β rescues sympathetic neurons from p53-induced cell death [250]. ΔNp73β 
overexpression is noticed in malignant NIH3T3 cells, and injection of these cells into mice 
generates tumors [290]. In mice, overexpression of ΔNp73α or ΔNp73β isoform protects neurons 
from apoptosis induced upon withdrawal of the nerve growth factor (NGF). ΔNp73 isoforms are 
predominantly expressed in developing brain of mice [250], suggesting that ΔNp73 isoforms play 
important roles in brain development by counteracting p73- and p53-induced cell death. 
Full-length p73 is overexpressed in a variety of cancers. p73 expressing colorectal adenocarcinoma 
showed greater vascularity than p73-negative tumors [116]. In a human ovarian cancer cell line, 
overexpression of TAp73α causes an upregulation of DNA damage repair proteins and provides 
resistance towards DNA damaging agent treatments [323]. TAp73α represses drug-induced 
apoptosis in SCLC cells by preventing caspase-3 activation and PARP cleavage [235]. We 
identified that TAp73α induces the expression of Hsp72, prevents the loss of mitochondrial 
transmembrane potential and loss of lysosomal membrane permeability, and thereby inhibits drug-
induced apoptosis in SCLC [237]. We also reported that TAp73α represses the enzymatic activity of 
caspase-2 and inhibits caspase-2-induced Bax activation, as well as loss of mitochondrial 
transmembrane potential, thereby protecting SCLC cells from caspases-2-induced apoptosis [218]. 
 
6.2. Role of p73 in cell death 
Cell division, proliferation and differentiation are important for the formation of organs and for the 
proper function of the immune system. Cell division is a biological process that generates new cells. 
As a result of cell division, huge numbers of cells are produced every day in the human body. 
Therefore, cell division has to be carefully regulated during all stages of the life of an individual to 
maintain tissue homeostasis. Different types of cell death mechanisms counterbalance the excess 
cells and control cell number. Cell death is also a defensive mechanism that removes infected, 
mutated or damaged cells. Abnormal cell growth can occur due to defects in cell death mechanisms. 
Transcriptional dependent and independent activities of p73 are involved in regulation of cell death.  
p73 transactivates genes, which are involved in apoptosis. TAp73α, β and γ transactivates the CD95 
gene promoter [220]. p73 transactivates the BAX gene promoter [208, 220] and induces Bax 
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translocation from cytosol to the mitochondria [208]. Puma induces apoptosis in a Bax/Bak-
dependent manner [208]. p73 induces the transcription of PUMA [208] and Puma promotes 
translocation of Bax to the mitochondria [358], thereby promoting Cyt c release from them. NOXA, 
a pro-apoptotic BH3 only member of the Bcl-2 family, is transactivated by p73 [200]. Scotin, a pro-
apoptotic protein located in the ER and nuclear membrane [34], promotes caspase-dependent 
apoptosis upon UV irradiation. p73α transactivates the SCOTIN gene promoter [309]. Our group 
found that, TAp73β induces the expression of p57Kip2, which contributes to mitochondria-mediated 
apoptosis.  
Overexpression of p73 induces apoptosis in various cancer cell lines [158, 241]. In NCI-H82 cells 
overexpression of TAp73β promotes apoptosis upon drug treatment. In DU-145 prostate cancer 
cells, caspase-1 overexpression enhances apoptosis after ionizing radiation [338]. Lung endothelial 
cells of caspase-1
-/- 
mice showed a reduction in the serum withdrawal-induced apoptosis [159], 
suggesting that caspase-1 plays an important role in apoptosis. TAp73α and TAp73β can 
transactivate the CASPASE-1 gene promoter [137]. Loricrin, a major component of the cornified 
cell envelope, can induce programmed cell death [348] and LORICRIN gene promoter is 
transactivated by TAp73γ [68]. Transcriptional regulation of various pro-apoptotic gene promoters 
like NOXA, BAX, SCOTIN and CD95 can explain the isoform-specific involvement of p73 in 
apoptosis. Apart from regulating cell proliferation, the transcription factor E2F1 is also involved in 
the induction of apoptosis. E2F1 directly transactivates TAp73. Functional inactivation of p73 
reduces E2F1-induced apoptosis [135], suggesting that p73 plays an important role in E2F1-induced 
apoptosis. 
Many chemotherapeutic drugs induce the expression of p73, which in turn enhances drug-induced 
apoptosis [158]. Downregulation of p73 results in the inhibition of cisplatin-induced apoptosis [4]. 
Upon drug treatments, p73 elicits apoptosis in a caspase-dependent manner. In chemosensitive head 
and neck squamous cell carcinoma (HNSCC) Ca9-22 cells, p73 is responsible for etoposide-
induced caspase-8 activation and apoptosis [189]. Knockdown of p73 using small interfering 
ribonucleic acid (siRNA) blocks caspase-3 and -7 activities in etoposide-treated Ca9-22 cells, 
suggesting its role in activation of caspase-3 and -7 [189]. Reduced cytotoxicity of 
chemotherapeutic drugs upon inhibition of p73 expression, suggests the importance of p73 in 
sensitizing cells to cancer treatments. p73 is cleaved by caspases both in vitro and in vivo during 
apoptosis induced by DNA damaging drugs and its cleaved fragments are localized to mitochondria 
and augment tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis 
[276]. In support, purified recombinant TAp73α induces Cyt c release from isolated mitochondria 
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[276], suggesting that it has a transcription-independent activity in induction of the intrinsic 
apoptotic pathway. 
 
6.3. Factors influencing the cell life and death decisions by p73 
p73 is a multifunctional protein that regulates both cell life and cell death. Various cellular and 
environmental factors direct the regulation of cell life and death decision by p73. These factors 
influence the choice of genes to be transactivated by p73. TAp73 is able to transactivate its own 
intrinsic promoter (p2), thereby regulating the expression of anti-apoptotic ΔNp73 isoforms. As 
mentioned earlier, ΔNp73 isoforms are predominantly expressed in developing brain [250] and 
seem to protect neurons by counteracting p53- and p73-mediated apoptosis. A subset of tumor 
derived p53 mutants, but not WT p53, reduces the transcriptional activity of p73α on P21 and BAX 
gene promoters, hence reduce apoptosis induced by p73 [78, 295]. 
The impact of various isoforms of p73 in the transactivation of genes, which regulate cell cycle or 
apoptosis, differ [237, 362]. Our group reported that, in SCLC cells, TAp73α represses drug-
induced apoptosis, whereas TAp73β promotes it. Increasing levels of TAp73α inhibits the pro-
apoptotic effect of TAp73β in a dose-dependent manner, upon drug treatment and vice versa. 
Counteractions of TAp73α and TAp73β on each other’s function suggest that the more abundant 
isoform determines whether cell die or survive.  
p73 is acetylated by p300 after DNA damage. This acetylation activates the pro-apoptotic functions 
of p73 and directs it to transactivate pro-apoptotic gene promoters [59, 355]. A non-acetylatable 
mutant of p73 transactivates the cell cycle related P21 gene promoter, but not the pro-apoptotic 
P53AIP1 gene promoter [59]. Pin1 physically associates with p73, stabilizes it and promotes its 
transcriptional activity on genes involved in apoptosis [188, 191, 197]. Upon DNA damage, a 
cleaved fragment of protein kinase Cδ (PKCδ) phosphorylates serine residue 289 of p73β and 
enhances p73β-mediated apoptosis [258]. p73α mediated apoptosis is enhanced by Chk-1-mediated 
phosphorylation of p73α at serine residue 47 [111]. Upon DNA damage the transcriptional co-
activator Yap is activated by c-abl-dependent phosphorylation. Active Yap displays increased 
affinity to p73 and promotes selective recruitment of p73 on pro-apoptotic BAX and P53AIP1 gene 
promoters [179, 297]. In contrast, Akt-mediated phosphorylation of Yap suppresses Yap’s ability to 
promote p73-mediated transactivation of pro-apoptotic gene promoters [14].  
The apoptosis stimulating protein of p53 (ASPP) family consists of ASPP1, ASPP2 and iASPP 
(inhibitor of ASPP) [299]. DBD of p73 is responsible for the sequence-specific DNA binding and is 
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an interaction site for ASPP1 and ASPP2 [215]. This interaction specifically activates 
transcriptional activity of p73 on pro-apoptotic gene promoters like BAX, PUMA, and PIG3, but not 
cell cycle regulating P21 and MDM2 gene promoters [18]. p53 inactivation is upregulating the p73 
expression via E2F1-mediated transcription [313], suggesting that the presence of p53 can influence 
the relative levels of p73, thereby influencing the p73-mediated cell life or death decisions.  
In conclusion, regulation of cell life and death decisions by p73 is influenced by the presence of 
other p53 family members, type of p73 isoform (TA or ΔN) generated, balance between its pro- and 
anti-apoptotic isoforms, its association with various interacting partners and its post-transcriptional 
modifications. 
 
 
7. P73 in cancer 
Uncontrolled cell growth and spread of abnormal cells in various parts of the body are some 
features of cancer. If the spread is not controlled, it can cause the death of an individual. Various 
factors contribute to the generation of cancer. For example, UV radiation from sun causes skin 
cancer, smoke from tobacco causes lung cancer. Viral infections, such as hepatitis B virus (HBV), 
hepatitis C virus, and human papilloma virus (HPV) can cause cancer. In addition, metabolism 
within the cells produces free radicals as byproducts. These free radicals have the ability to cause 
DNA damage. It is estimated that an individual cell can suffer up to a million DNA changes in a 
day [56]. Our cells have developed exquisite DNA damage-repair mechanisms that protect us from 
DNA damage-related unfavorable outcomes [56]. During cell division DNA is replicated and 
segregated into daughter cells. A proper segregation of DNA into the daughter cells is very 
important for proper cell division and development of an organism. The cells have developed 
safeguarding mechanisms known as checkpoints, which ensure that everything is in order before 
allowing the next event to proceed during cell cycle progression.  
Various DNA repair mechanisms detect and repair the damaged DNA, and maintain its integrity . In 
the case of irreversible damage, cell death mechanisms are activated to eliminate unwanted or 
damaged cells. A failure to repair the damaged DNA can produce mutations. If these mutations are 
not repaired, e.g. due to failure of protection and repair mechanisms, they are passed on to the 
daughter cells. As a result mutated proteins with altered functions could be produced within the cell 
and may cause disturbances in the signaling mechanisms in which they are involved. Sometimes 
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these mutations negatively regulate signaling pathways associated with cell cycle, DNA damage 
repair, and cell proliferation, and thus enhance the risk of malignant transformation.  
Tumors are classified into various groups based on their primary site of origin, histological type, or 
type of body tissue from which they originate. Different types of tumors exhibit different 
clinicopathological features [169, 249, 287, 303, 342]. However, cancer cells share some general 
features, which are described as ‘‘the hallmarks of cancer’’. These common features include, self-
sufficiency in growth signals, evading programmed cell death, sustained angiogenesis, unlimited 
replicative or proliferative capability, tissue invasion and metastasis, and evading the growth 
suppress signals (for review, refer to [123]). 
The discovery of p53 was a major breakthrough in cancer biology research. Tumor suppressive 
functions of the p53 protein are linked to its ability to transactivate a variety of target genes that 
regulate DNA damage repair, cell cycle progression and apoptosis, and participate in a number of 
different signaling cascades. Mutations in the P53 gene can produce transcriptionally inactive p53 
proteins that have lost their tumor suppressive function [216, 261]. Compared to P53, mutations in 
P73 are very rare. However, amino acid substitutions or deletions in p73 were identified in a variety 
of cancer derived cells, e.g. the G264W mutation in NSCLC NCI-H1155 cells, Del418 mutation in 
SCLC DMS92 cells, and Del603 mutation in lung carcinoma A427 cells [132, 349]. Deb et al., 
described a mutant of TAp73α in MCF-7 cells having two amino acid substitutions (R268Q, 
R300C) within the DBD region [69]. Two mutations were identified in neuroblastomas (NBLs), one 
somatic (P405R) and one germline (P425L), which are amino acid substitutions at the carboxy-
terminal region of p73 [134]. In a primary tumor of a breast cancer patient, one somatic missense 
mutation of glutamine from arginine at codon 269 within exon 7 was reported [122]. 
 
Although P73 is rarely mutated, altered expression levels of p73 and its abnormal splicing variants 
were identified in several human cancers [178]. Decreased levels of p73 were identified in 
pancreatic adenocarcinoma [190], breast cancer [3], thyroid cancer [96] and osteosarcoma [244]. In 
some hepatocellular carcinoma (HCC), increased levels of p73 expression were identified and this 
was correlated with a lower mean survival time for the patients [307]. Increased expression of 
TAp73α was identified in cancers such as cervical cancer [331], medulloblastoma [363], B-cell 
chronic lymphocytic leukaemia [234], ovarian carcinoma [231], gastric adenocarcinoma [151], 
bladder cancer [347] and thyroid cancer [104]. ΔNp73 isoforms are frequently upregulated in some 
tumors compared with their normal tissue of origin [353]. ΔNp73 isoforms express pro-oncogenic 
properties and act as dominant negative inhibitors over pro-apoptotic TAp73 and p53 by physically 
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interacting with them [223, 224, 353]. Thus, ΔNp73 isoforms functions as oncoproteins and can 
contribute to the cancer progression. Interestingly, TAp73α, β and γ isoforms are able to induce 
transcription of ΔNp73 promoter [331]. Increased expression of TAp73α in a variety of human 
cancers and its ability to transactivate oncogenic ΔNp73 suggests it could be a pro-oncogene. In 
support, we identified that under certain experimental conditions, TAp73α  exhibits anti-apoptotic 
effects, for example, it protects SCLC NCI-H82 cells from caspase-2, as well as from drug-induced 
apoptosis. However, these oncogenic effects of TAp73α seem to be restricted to certain cell types.  
 
In Saos-2 (Sarcoma osteogenic) cells, mutated p53 causes functional inactivation of p73 by 
physically interacting with it, thereby promoting Saos-2 colony formation [199]. Physical 
interaction between mutant p53 and p73 also inhibits the transcriptional activity of p73 on P21, a 
cell cycle regulator [106]. Hence, functional inactivation of p73 seems to be one reason for cancer 
in p53 mutated cells. Increased incidences of spontaneous tumors are noticed in TAp73 null mice 
[312]. As mentioned earlier, a more aggressive tumor phenotype (higher tumor burden and 
metastases) and shorter life span was noticed in P53
+/− 
P73
+/− 
mice than P53
+/− 
mice [100, 226], 
suggesting p73 might be compensating for the loss of p53 tumor suppressive functions in P53
+/−  
mice. Loss of heterozygosity (LOH) of the P73 was observed in esophageal cancer [229], 
hepatocellular cancer [209], gastric cancer [178], neuroblastoma and breast cancers [149, 164, 266, 
285]. Moreover, in primary neuroblastoma tumors, low levels of p73 expression were identified 
[233]. Furthermore, p73 inhibits vascular endothelial growth factor (VEGF) gene expression [272], 
strongly supporting its tumor suppressive functions. 
 
p53 family members are involved in regulation of cell cycle and cell death. In a variety of cancer 
treatments, the used drugs target cell cycle or cell death pathways. Our data indicate that TAp73α 
and TAp73β elicits opposite effects (anti- and pro-apoptotic effects, respectively) on drug-induced 
apoptosis. Thus, consideration of the status of p73 isoform expressions seems to be necessary 
during chemotherapy, otherwise the selected drugs might promote cancer progression rather than 
curing it.  
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8. Aim of the thesis  
 
 To determine isoform-specific transcriptional activities of p73 that influence drug-induced 
apoptosis. 
 To uncover the molecular mechanisms of p73 isoforms by which they exhibit pro- and anti-
apoptotic effects. 
 To elucidate the structural and functional requirements for p73 to regulate cell life and death 
decisions. 
 To discover the transcriptional activities of various isoforms of p73 on cell cycle and 
apoptosis related gene promoters based on the context of the cell. 
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9. Results 
 
9.1. Paper I 
Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells. 
Our group previously showed that TAp73α inhibits etoposide-induced apoptosis in SCLC, whereas 
TAp73β promotes it. Increasing levels of TAp73α inhibited apoptosis promoted by TAp73β upon 
etoposide treatment. Different isoforms of p73 differently transactivate genes, which are involved in 
various biological processes [362]. We speculated that opposite effects TAp73α and TAp73β on 
drug-induced apoptosis might be due to isoform-specific transcriptional activities. 
Hsp72 is an anti-apoptotic protein and acts at multiple levels on the apoptotic signalling pathway 
[80]. It inhibits lysosomal membrane permeabilization [23, 119], JNK and translocation of Bax to 
the mitochondria [183]. It interacts with AIF [257] and Apaf-1 [271], inhibits the processing of 
caspase-9 and -3 [16, 180], thereby inhibiting progression of apoptosis. 
We speculated that the anti-apoptotic effects of TAp73α in SCLC might be associated with its 
transcriptional activity and that it might transactivate the anti-apoptotic HSP72. We found that 
TAp73α, but not TAp73β transactivates HSP72 promoter, induces Hsp72 mRNA levels and Hsp72 
protein expression. 
In NCI-H82 cells, antisense knockdown of Hsp72 resulted in an abolishment of the anti-apoptotic 
effect of TAp73α upon drug (etoposide) treatment. Moreover, Hsp72 knock down resulted in 
activation of Bax, loss of mitochondrial membrane potential and lysosomal membrane 
permeabilization in these cells even in the presence of TAp73α. 
Interestingly, overexpression of Hsp72 abolished the pro-apoptotic effects of TAp73β upon drug 
treatment. Furthermore, our results suggested that TAp73β counteracts the anti-apoptotic effects of 
TAp73α by preventing its transcriptional activities on HSP72 promoter.  
Inhibitory effects of TAp73α on drug-induced apoptosis are associated with its ability to inhibit 
caspase-3 and PARP cleavage. Interestingly, under similar conditions TAp73β promoted both 
caspase-3 and PARP cleavage [235]. In addition to the previous reports on pro- and anti-apoptotic 
effects of p73 isoforms, our study on transcriptional activities of carboxy-terminal TAp73 isoforms 
provides evidence that they govern the cell life and death decisions at the transcriptional level. 
Moreover, our studies explain a molecular mechanism on how certain tumors with TAp73α 
overexpression are resistant to drug treatments. 
38 
 
9.2. Paper II  
TAp73α protects small cell lung carcinoma cells from caspase-2-induced mitochondrial 
mediated apoptotic cell death. 
In paper I, we demonstrated that anti-apoptotic effects of TAp73α are mediated by Hsp72 in SCLC 
NCI-H82 cells. Apart from transactivating anti-apoptotic genes, TAp73α is also able to inhibit the 
activation of pro-apoptotic proteins, for example, it inhibits caspase-3 activation and PARP 
cleavage, thereby negatively regulating apoptosis [235]. 
Caspase-2 is the second caspase to be cloned and its overexpression induces apoptosis in various 
cell lines. During the progression of apoptosis, it cleaves full-length Bid to activated tBid and 
engages the mitochondria-dependent cell death pathway [28]. We speculated that TAp73α might 
exert anti-apoptotic effects by inhibiting caspase-2-induced apoptosis. In fact, our results 
demonstrate that TAp73α inhibits apoptosis induced by caspase 2. In contrast, under our 
experimental conditions TAp73β promoted caspase-2-induced apoptosis.  
Interestingly, TAp73α co-expression significantly reduced caspase-2 enzymatic activity in NCI-
H82 cells. Overexpression of caspase-2 promotes Bax translocation to the mitochondria and induces 
the mitochondrial mediated apoptotic cascade [28, 118, 170]. Co-expression of TAp73α prevented 
caspase-2-induced mitochondrial dysfunction and Bax activation. These results suggest that 
TAp73α operates at the initiation phase of apoptosis, upstream of mitochondria and at level of the 
Bax activation.  
To determine the structural domains that are required for the anti-apoptotic functions of TAp73α on 
caspase-2-induced apoptosis, we took advantage of plasmids encoding mutations in 
different functional domains of TAp73α. Our mutational studies revealed that TAp73α requires the 
functional DBD and SAM domain for its anti-apoptotic effect, on caspase-2-induced apoptosis. 
In addition to the previously described anti-apoptotic effects of TAp73α, our findings provide 
biochemical and molecular mechanisms on how TAp73α negatively influences the caspase-2-
induced apoptosis in SCLC cells.  
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9.3. Paper III 
TAp73β transcriptional target gene p57Kip2 promotes p73β-mediated mitochondrial apoptotic 
cell death. 
In papers I and II, we showed the molecular mechanisms on how TAp73α exerts anti-apoptotic 
functions upon drug-induced apoptosis. In these papers, we also reported that drug (etoposide) and 
caspases-2-induced apoptosis were enhanced by TAp73β. TAp73β has been shown to be a potent 
inducer of apoptosis as compared to the TAp73α [161, 288]. In paper III, we aimed to identify the 
TAp73β regulated molecular mechanisms that execute its pro-apoptotic effects.  
p57
Kip2
 is a CKI and holds tumor suppressive functions. p57
Kip2 
expression levels are downregulated 
in a variety of human cancers [31] and loss of its expression was correlated with poor survival rate 
of cancer patients with laryngeal squamous cell carcinoma [92]. Overexpression p73β, but not p73α 
or p73γ, induces the expression of p57Kip2 [26]. It has been shown that p57Kip2 potentiates drug-
induced apoptosis [273]. We hypothesised that the pro-apoptotic effects of TAp73β might be 
depend on its ability to induce expression of the p57
Kip2
 protein.  
In this paper, we demonstrate that in various cell lines TAp73β, but not TAp73α, induces 
expression of p57
Kip2
. Gonzalez et al., reported that p57
Kip2 
mediates pro-apoptotic activity of p73β 
[112]. However, the precise mechanism by which TAp73β regulates the p57Kip2 expression and its 
roles in TAp73β-induced apoptosis was unclear. In this study, we reveal that TAp73β, but not 
TAp73α, binds to a putative p53RE located at 1753 base pairs upstream of P57Kip2 transcription 
initiation site. Furthermore, transcriptional activity of TAp73β on the P57Kip2 promoter is 
counteracted by TAp73α. To detect whether pro-apoptotic effects of TAp73β upon drug treatment 
are mediated by p57
Kip2
, we took advantage of siRNA-mediated silencing of p57
Kip2
 expression. 
Overexpression of TAp73β and p57Kip2 promoted staurosporine (STS)-induced loss of 
mitochondrial membrane potential and apoptosis in HeLa cells. siRNA-mediated silencing of 
p57
Kip2
 repressed TAp73β-induced mitochondrial dysfuntion, Bax activation and apoptosis. These 
results suggest that upon drug treatment, p57
Kip2
 sensitizes these cells to TAp73β-induced apoptosis 
via engaging the mitochondria-mediated apoptotic pathway. The present data reveals a possible 
mechanism to often observed pro-apoptotic activities of TAp73β.  
Our data provide an additional evidence for the target-specific transcriptional activities of carboxy-
terminal TAp73α and TAp73β isoforms that mediate their anti- and pro-apoptotic effects, upon drug 
treatments.  
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9.4. Paper IV 
DNA binding domain independent transcriptional activity of p73 depends on the p53 status of 
the cell. 
The p73 isoforms have been shown to have different transcriptional activity [362] and they have 
distinct roles during various stages of development [215, 219]. Interplay between the p53 family 
members has been shown to have a significant effect on development, proliferation, tumorigenesis 
and response to anti-cancer treatments [101, 144, 175, 192]. In papers I and III, we reported that 
TAp73α and TAp73β exhibit opposite effects on drug-induced apoptosis and their anti- and pro-
apoptotic effects partly depend on their target-specific transcriptional activities. 
P53 is commonly mutated or deleted in a variety of human cancers. In contrast to the P53, P73 
mutations are more seldom reported in human cancers and cancer derived cells [70, 122, 132, 134, 
222, 247, 349]. Mice lacking the TAp73 isoforms exhibit increased incidence of spontaneous 
tumors [311]. On the other hand, altered expression levels of various isoforms of p73 and 
expression of its abnormal splicing variants are noticed in several cancers [3, 82, 96, 104, 151, 230, 
234, 244, 317, 332, 347, 363]. Certain tumor-derived mutants of p53 interact with TAp73 isoforms 
and inhibit their transcriptional activity [79, 106, 192, 294, 337]. It is thus important to take into 
account that the mutations in TAp73 may influence the biological functions of a subset of p53 
mutants and/or p53. 
In this paper, we aimed to identify cell context-specific functions of p73 isoforms. We hypothesized 
that TAp73, TAp73β and ΔNp73 isoforms and DBDmut p73, which contains two amino acid 
substitutions (R268Q and R300C) within its DBD region [70], exhibit cell type-specific 
transcriptional activities. Indeed, our gene reporter assays (GRAs) revealed that they exhibit 
different transcriptional activities in different cell lines on cell cycle and apoptosis related BAX and 
P21 gene promoters. Interestingly, we identified that DBDmut p73α transactivates the P21 gene 
promoter in HEK-293 cells, but fails to transactivate the same promoter in NCI-H82 cells. Our 
subsequent GRAs using wild-type (WT) p53 and p53 null cells and siRNA-mediated silencing of 
p53 in HEK-293 cells revealed that the ability of of DBDmut p73α to transactivate P21 gene 
promoter depends on the p53 status of the cell. We further identified that upon co-expression 
DBDmut p73α and p53 physically interact with each other and stabilize their respective protein 
expression level in cells. Furthermore, we identified that co-expression of p53 promotes nuclear 
localisation of the DBDmut p73α. To identify whether p53 promoted nuclear localization of  
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DBDmut p73α promotes its recruitment on P21 promoter, we performed ChIP experiments in 
HEK-293T cells. Our ChIP experiment revealed that p53 was required for the recruitment of 
DBDmut p73α to the P21 promoter. 
Our findings suggest that in different cells transcriptional activities of isoforms of p73 are different 
and their transcriptional activities depend on the context of the cell. Furthermore, our findings 
reveal a functional cooperation network between p53 and p73, where DBDmut p73α seems to act as 
a transcriptional co-factor for p53.  
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10. General discussion and Future perspectives 
p53 was identified in 1979 and it attracted the interest of numerous researchers because the P53 
gene was found to be frequently mutated or deleted in a variety of human cancers. Initially P53 was 
thought to be an oncogene, however, its tumor suppressor functions were well established in 1989 
[13]. p73, a structural homologue of p53 was identified in 1997. The structural similarity initially 
suggested that it might share functional similarities with p53 [178]. Indeed, p73 shares functional 
properties with p53 and it recognizes p53REs with its DBD, and transactivates them with its TAD. 
p73 transcriptionally regulates various biological processes such as differentiation, development, 
cell cycle and apoptosis. Though p73 shares structural and functional similarities with p53, it also 
has its own biological functions.  
The p73 isoforms have distinct transcriptional activities, for example, in yeast, mouse and human 
cells, they exhibit different capability to transactivate p53 regulated promoters [78, 186, 208, 251, 
289] and specific target genes [26, 361]. Full-length TAp73α and TAp73β differently regulate cell 
cycle progression [321], apoptosis [66, 112, 235, 362] and differentiation [181]. 
Full-length transcriptionally active TA isoforms of p73 are considered to act as tumor suppressors. 
Transactivation domain-deficient ∆N isoforms of p73 act functionally analogous to other 
oncoproteins by inactivating the transcriptional activity and apoptosis induced by p53 and TAp73. 
Thus ΔNp73 isoforms are regarded as oncoproteins. Overexpression of ∆Np73 isoforms was 
identified in a variety of human cancers further supporting their oncogenic properties. Interestingly, 
overexpression of the pro-apoptotic TAp73α isoform was identified in several human cancers such 
as gastric adenocarcinoma [151], thyroid cancer [104], ovarian carcinoma [231], prostate cancer [8] 
and bladder cancer [347]. Moreover, in an ovarian cancer cell line, overexpression of TAp73α 
results in resistance to chemotherapeutic agents [322]. Nyman et al., reported that TAp73α inhibits 
drug-induced apoptosis in a cell type-dependent manner [218]. It was shown that overexpression of 
TAp73α cause chemoresistance, but the precise mechanism to how it does so is not yet fully 
understood. As p73 can transcriptionally regulate various biological processes, we wanted to 
identify whether the apoptosis inhibitory effects of TAp73α depend on its transcriptional activity. 
The cell survival protein Hsp72, a member of the heat shock family of proteins, inhibits apoptosis at 
multiple levels. In several cancers overexpression of Hsp72 was reported [55, 105, 274] and a 
variety of chemotherapeutic drugs induce expression of Hsp72 that results in decreased 
chemosensitivity of cancer cells. Moreover, ΔNp73α induces expression of Hsp72 [305]. In paper I, 
we report that TAp73α induces the expression of Hsp72 and that its anti-apoptotic effects partially 
depend on the  
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induction of Hsp72. Interestingly, TAp73β did not induce Hsp72 expression. TAp73α 
transactivation of HSP72 can to some extent explain the anti-apoptotic properties of TAp73α and its 
involvement in the resistance to chemotherapeutic agents in certain cell types. 
In SCLC cells, TAp73α represses drug-induced apoptosis, upstream of the mitochondria at the level 
of Bax activation. Caspases cleave several substrates in the cell and promote the progression of 
apoptosis. Caspase-2 acts upstream of mitochondria and promotes Cyt c release during drug-
induced apoptosis [263]. Active caspase-2 engages mitochondria in apoptosis by directly cleaving 
full-length Bid to activated tBid and promotes Bax translocation to the mitochondria.  
In an attempt to elucidate the molecular mechanisms by which TAp73α mediates its anti-apoptotic 
effects, we tested whether it can inhibit caspases-2-mediated apoptosis. In paper II, we report that 
TAp73α inhibits caspase-2-induced apoptosis through inhibiting caspase-2 enzymatic activity, Bax 
activation, and loss of mitochondrial transmembrane potential and resulting apoptosis. In contrast, 
TAp73β promoted caspase-2-induced apoptosis. In an attempt to identify the domains required for 
TAp73α to elicit anti-apoptotic effects, we found that the DBD and SAM domains of TAp73α are 
required for its inhibitory effect on caspase-2-induced apoptosis in SCLC cells. Requirement of the 
SAM domain suggests that binding of specific co-factors influences its anti-apoptotic effects. This 
hypothesis is further supported by SAM deleted TAp73α failing to inhibit caspase-2-induced 
apoptosis, and rather significantly promoted it. Certainly, TAp73β, which does not have the SAM 
domain, seems to be not able to associate with inhibitory molecules, thus seems to promote 
caspases-2-induced apoptosis. Previous studies have focused  on transcriptional activities of p73 to 
explain its pro- and anti-apoptotic activities. Identifying its transcription-independent activities in 
regulation of cell life and death decisions is also an interesting area of p73 research.  
p57
Kip2
, a cyclin-dependent kinase inhibitor, regulates cell proliferation and acts as a tumor 
suppressor protein. Recent studies revealed that p57
Kip2 
mediates drug-induced mitochondria-
mediated cell death [325]. In paper III, we reveal that TAp73β, but not TAp73α, induces the 
expression of p57
Kip2
. Furthermore, knockdown of p57
Kip2 
showed that TAp73β-induced p57Kip2 
expression contributes to mitochondria-mediated apoptotic events.  
The observation based on papers I, II and III, suggests that carboxy-terminal TAp73α and TAp73β 
isoforms exhibit opposite effects on cell life and death decisions. In these papers, we also showed 
that TAp73α and TAp73β counteract each other’s pro- and anti-apoptotic functions in a dose-
dependent manner. It seems that the balance between amino- and carboxy-terminal isoforms play 
important roles in overall tumor development and chemoresistance. Therefore, consideration of the 
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presence of specific isoform of p73 and their relative level of expression in cancer cells seem to be 
necessary during cancer therapy to achieve an effective treatment.  
These opposite effect on cell life and death decision and differential transcriptional activity of p73 
isoforms might be influenced by structural differences at their carboxy-terminal region. TAp73α, 
but not TAp73β, possess a carboxy-terminal SAM domain, which is expected to be involved in 
protein-protein interactions. It has been shown that several transcriptional co-activators physically 
interact with p73 at the carboxy-terminal region and regulates its transcriptional activity. 
Differential binding of co-factors to their carboxy-terminal region might be one of the reasons for 
their differential transcriptional activity.  
Functional differences between p73 isoforms were previously described. TAp73α was shown to 
repress drug-induced apoptosis in SCLC cells, but to promote it in NSCLC cells [235]. In yeast, 
mouse and human cells, isoforms of p73 show different ability to transactivate p53 regulated 
promoters [78, 186, 208, 251, 289]. Functional cooperation between p53 family members was 
previously described. For example, a more aggressive tumor phenotype (higher tumor burden and 
metastases) and shorter life span were noticed in P53
+/− 
P73
+/− 
mice, compared to P53
+/− 
mice [100, 
226], indicating that p73 functionally compensates the loss of p53 in the P53
+/− 
mice. Some mutants 
of p53 physically interact with p73 and inhibit its transcriptional activity [106, 297], whereas some 
mutants of p53 bind to p73, but do not alter its transcriptional activity [106]. In paper IV, we report 
that in different cell lines, isoforms of p73, e.g. TAp73α, TAp73β and a DBD mutant of TAp73α 
transactivate P21 or BAX promoters with different capabilities. In this paper, we also report a 
functional cooperation between DBDmut TAp73α and p53. In p53 null cells, DBDmut p73α is 
transcriptionally inactive and fails to transactivate either cell cycle or apoptosis regulating gene 
promoters (P21 and BAX promoters, respectively). Interestingly, DBDmut p73α was able to 
transactivate the P21 promoter only in p53 expressing cells. In this paper, we report that p53 
promotes nuclear localization of DBDmut p73α and promotes its recruitment at the P21 promoter. 
Our observations suggest that the context of the cell influences the transcriptional activity of 
DBDmutp73α.  
Various isoforms of p73 have their specific transcriptional target genes and an individual isoform 
can differentially transactivate the same gene based on the cell type. The transactivation ability of a 
specific isoform seems to be dependent on the context of the cell, its association with various 
interaction partners, and the presence of certain transcriptional co-factors. Its association with 
ASPP1 and/or ASPP2 induces the transcriptional activity of p73 to transactivate pro-apoptotic gene 
promoters, e.g. BAX and PUMA, but not cell cycle regulating P21 and oncogene MDM2 gene 
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promoters [18]. Different post-translational modifications of p73 were shown to direct it towards 
the selective induction of either cell cycle arrest or apoptosis [59, 65]. Not only the transcriptional 
activities of p73, but also its cellular signaling activities seem to influence the fate of the cell [276]. 
As various isoforms of p73 seem to exhibit different roles in biological processes depending on the 
cell context, it is very interesting to identify their effect on the fate of the cell at different stages of 
development based on the cell context. It is important to identify the functions of specific isoforms 
of p73 as they are frequently deregulated in various types of human cancers. A better understanding 
about individual isoform functions based on the cell context might help us to develop new strategies 
that in the future can more effectively target the tumor. 
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11. Concluding remarks  
This thesis reveals transcriptional and molecular mechanisms about how different isoforms of p73 
regulate cell life and death decisions of the cell.  
In paper I, we identified that TAp73α inhibits drug-induced apoptosis, whereas TAp73β promotes 
it. TAp73α, but not TAp73β, induces the expression of the cell survival protein Hsp72, by 
transactivating its promoter. Antisense knockdown of Hsp72 results in an abolishment of the anti-
apoptotic effect of TAp73α in SCLC cells upon etoposide treatment, suggesting that Hsp72 
expression mediates its anti-apoptotic effects. Moreover, Hsp72 co-expression  prevents the pro-
apoptotic effects of TAp73β. Furthermore, TAp73β counteracts the anti-apoptotic effect of TAp73α 
by inhibiting TAp73α-induced Hsp72 expression in a dose-dependent manner.  
In paper II, we revealed that TAp73α represses caspase-2-induced apoptosis via inhibition of its 
enzymatic activity in NCI-H82 cells. Co-expression of TAp73α inhibits caspase-2-induced Bax 
activation, LMMP and resulting apoptosis. Furthermore, we identified that TAp73α requires the 
functional DNA binding domain and SAM domain for its anti-apoptotic effect, on caspase-2-
induced apoptosis. 
In paper III, we identified that P57
Kip2
 is a direct target gene for TAp73β, but not for TAp73α. We 
identified a potential p53 response element within the P57
Kip2 
promoter region for the recruitment of 
TAp73β. Furthermore, TAp73α counteracts TAp73β transcriptional activity on the P57Kip2 promoter 
and it inhibits TAp73β-induced expression of p57Kip2 in a dose-dependent manner. Moreover, 
TAp73β-induced p57Kip2 sensitizes HeLa cells to apoptosis through the mitochondrial apoptotic 
pathway.  
In paper IV, we reveal that TAp73α, TAp73β and ΔNp73α transactivate P21 or BAX promoters with 
different capabilities. We identified a functional cooperation between p53 and DBDmutp73α. The 
transcriptional ability of DBDmut p73α to transactivate the P21 promoter seems to depend on the 
p53 status of the cells. DBDmutp73α and p53 physically interact with each other and they stabilize 
each other’s expression. Moreover, DBDmut p73α is localized both in the cytoplasm and nucleus, 
and co-expression of p53 promotes the nuclear localization of DBDmut p73α. Furthermore, co-
expression of p53 promotes recruitment of DBDmut p73α to the P21 promoter. 
Finally, different isoforms of p73 influences cell life and death decisions differently upon drug 
treatments and this activity seems to depend on the context of the cell and its isoform-specific 
transcriptional activities. Furthermore, p53 family members have functionally cooperating networks 
that influence each other’s transcriptional activities. 
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In our future studies, we will extend our investigations on the pro- and anti-apoptotic effects of p73 
isoforms upon drug treatment in various cell lines based on the context of the cell. The potential 
role of p73 as a target for cancer treatment will be investigated by analysis of its expression level 
and its effect on different drug treatments in different patient materials. p73 isoform-specific 
interacting partners will be identified in various cells based on the cell context. Furthermore, 
influence of identified interacting partners over the pro- and anti-apoptotic functions of p73 will be 
investigated. The possible mechanisms, which influence the stabilization of both p53 and DBDmut 
p73α will be investigated based on the context of the cell. Future studies will focus on identification 
of other pro- and anti-apoptotic transcriptional target genes of p73. Furthermore, involvement of 
these target genes in mediating cell life and death decision will be investigated. Moreover, we will 
extend our studies in vivo and a group of mice will be transplanted with TAp73α and TAp73β 
overexpressing tumors, drug or mock-treated, and tumor growth will be monitored over time. 
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